CureVac (CVAC) Projected to Post Quarterly Earnings on Tuesday

CureVac (NASDAQ:CVAC) is expected to be releasing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect CureVac to post earnings of ($0.17) per share and revenue of $21.40 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 11, 2025 at 9:00 AM ET.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings results on Thursday, August 21st. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.15). CureVac had a net margin of 38.21% and a return on equity of 29.57%. The business had revenue of $1.41 million during the quarter, compared to the consensus estimate of $4.27 million. On average, analysts expect CureVac to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CureVac Stock Down 0.7%

Shares of NASDAQ:CVAC traded down $0.04 during trading hours on Tuesday, hitting $5.31. The company’s stock had a trading volume of 72,094 shares, compared to its average volume of 827,876. The firm’s fifty day moving average price is $5.37 and its 200 day moving average price is $4.98. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.17 and a quick ratio of 6.16. CureVac has a 52 week low of $2.37 and a 52 week high of $5.72. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of 5.53 and a beta of 2.51.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “hold (c-)” rating on shares of CureVac in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, CureVac has a consensus rating of “Hold” and an average price target of $6.83.

Institutional Investors Weigh In On CureVac

A number of hedge funds have recently modified their holdings of the company. Headlands Technologies LLC purchased a new position in CureVac during the second quarter worth about $35,000. Integrated Wealth Concepts LLC boosted its stake in CureVac by 25.0% during the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock worth $42,000 after buying an additional 3,000 shares during the period. Gabelli Funds LLC acquired a new stake in shares of CureVac during the second quarter worth about $130,000. Cubist Systematic Strategies LLC acquired a new stake in shares of CureVac during the first quarter worth about $142,000. Finally, AQR Arbitrage LLC acquired a new stake in shares of CureVac during the second quarter worth about $240,000. Hedge funds and other institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.